



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학박사 학위논문

**Effects of pravastatin on diabetic cardiomyopathy  
according to the blood glucose control  
in type 1 diabetic rats**

제 1 형 당뇨 쥐에서 혈당 조절에 따라  
프라바스타틴의 복용이 당뇨병성 심근병증의  
진행에 미치는 영향

2018 년 8 월

서울대학교 대학원

의학과 마취통증의학 전공

민 정 진

# Abstract

## Effects of pravastatin on diabetic cardiomyopathy according to the blood glucose control in type 1 diabetic rats

Jeong Jin Min

Dept. of Anesthesiology and Pain Medicine

Seoul National University School of Medicine

**Background:** Although statins have been suggested to attenuate the progression of diabetic cardiomyopathy, it remains unclear whether statins are protective in diabetic hearts when blood glucose is not controlled. We evaluated the effect of pravastatin on diabetic rat hearts according to the presence of glycemic control.

**Methods:** Seven-week-old male Lewis rats (n = 87) were randomly divided into five groups: control (group C), diabetes (D), diabetes with insulin (I), diabetes with pravastatin (P), and diabetes with insulin and pravastatin (IP). Diabetes was induced using a single intravenous injection of streptozotocin (65 mg/kg). After diagnosing diabetes (blood glucose > 300 mg/dl), insulin (2-10 U/kg, twice a day) and/or pravastatin (20-25 mg/kg/day) were administered depending on the group assignment. Eight weeks after diabetic induction, the heart was extracted following echocardiography. Cardiac fibrosis was analyzed using Masson's trichrome stain. Cardiac expression of collagen I/III, matrix metalloproteinase (MMP)-2, MMP-9, and angiotensin converting enzyme (ACE)/ACE2 were evaluated by

immunohistochemistry and/or Western blot. Enzyme-linked immunosorbent assay was used for measuring reactive oxygen species (ROS).

**Results:** Diabetic groups without glycemic control (groups D and P) showed significantly impaired diastolic function and significantly increased levels of cardiac fibrosis, collagen I/III, MMP-2, and MMP-9. ROS production was also significantly increased in groups D and P. However, there were no significant differences in most outcomes among the control and two glucose-controlled diabetic groups (groups I and IP). Cardiac ACE2 expression was more preserved, while ACE expression was lower in groups C and IP than in the other groups (D, I, and P).

**Conclusion:** Our study suggests that glycemic control using insulin rather than pravastatin attenuates the progression of diabetic cardiomyopathy. However, further study is required to evaluate the usefulness of statins in protecting diabetic hearts.

**Keywords:** pravastatin, insulin, diabetic cardiomyopathy, cardiac fibrosis, angiotensin converting enzyme-2, reactive oxidative species

**Student Number:** 2013-30541

## Contents

I. Introduction	-----	1
II. Materials and Methods	-----	4
III. Results	-----	9
IV. Discussion	-----	20
References	-----	27
Korean Abstract	-----	32

## List of Figures

- Fig. 1.** Masson's trichrome stain of the myocardium with the connective tissues stained blue ----- 13
- Fig. 2.** Representative micrograph of immunohistochemistry (A) and Western blot photograph for cardiac protein expression (B) of collagen I. ----- 14
- Fig. 3.** Representative micrograph of immunohistochemistry (A) and Western blot photograph for cardiac protein expression (B) of collagen III ----- 15
- Fig. 4.** Representative Western blot photographs for cardiac protein expression of MMP-2 (A) and MMP-9 (B) ----- 16
- Fig. 5.** Cardiac expressions of reactive oxygen species measured by enzyme-linked immunosorbent assay ----- 17
- Fig. 6.** Representative micrographs of immunohistochemistry for ACE (A) and ACE2 (B), and Western blot photographs for cardiac protein expression for ACE (C) and ACE2 (D) ----- 18

## List of Table

<b>Table 1.</b> Demographic, laboratory and echocardiographic data after eight weeks of treatment -----	12
--	----

# Introduction

Diabetes affects almost every organ system of the body, leading to serious complications. Especially, cardiovascular involvement of diabetes has considered as the most common cause of death in diabetic patients. [1] Diabetic cardiovascular complications are clinically manifested as following three different types: coronary artery disease related to atherosclerosis, diabetic cardiac autonomic neuropathy, and diabetic cardiomyopathy.[2, 3]

Among the cardiac complications of diabetes, diabetic cardiomyopathy was introduced in 1972 based on the postmortem examinations in four diabetic patients who had heart failure without any other comorbidity.[4] Diabetic cardiomyopathy is a separate disease from other well-established diabetic cardiovascular complications (e.g., coronary artery disease and cardiac autonomic neuropathy) and increases the risk of heart failure and cardiac mortality.[2, 3] The pathophysiology of diabetic cardiomyopathy is considered as multifactorial, and several suggested mechanisms include impaired calcium homeostasis, lipotoxicity, mitochondrial dysfunction, increased oxidative stress, and renin-angiotensin system activation.[3] The intracellular renin-angiotensin system in diabetic heart is over-activated by hyperglycemia and the activated renin-angiotensin system promotes the extracellular matrix in diabetic heart.[5]

Because of the cardiovascular protective effects, statin (3-Hydroxy-methylglutaryl coenzyme A reductase inhibitors) is generally recommended in diabetic patients with cardiovascular risk factors or overt cardiovascular disease.[6] Many previous

studies have shown that statins are effective to prevent major cardiac and cerebrovascular events, independently its cholesterol-lowering effect. [7, 8] This “pleiotropic” effect of statins has suggested to be related with improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response. [9-11]

Statin treatment has also been suggested to reduce the progression of diabetic cardiomyopathy. Protective effects of statins on diabetic cardiomyopathy have been reported to improve cardiovascular remodeling by suppression of arterial wall thickening and myocardial fibrosis, restoration of left ventricular diastolic function, preservation of cardio-protective angiotensin-converting enzyme-2 (ACE2), inhibition of inflammatory markers such as matrix metalloproteinases (MMP), and reduction of oxidative stress.[9, 12-15]

However, in the clinical field, statin is not considered as a first-line drug and is never used alone in diabetic patients. From the clinician’s point of view, the real effect of statin should be evaluated in the glucose-controlled diabetic condition. In a previous study, a combination of fluvastatin and insulin appears to be more effective than insulin alone therapy in the diabetic heart.[13] However, considering that glucose control by insulin is the main therapy for diabetes, whether a clinical dose of statin would also be protective in cases where blood glucose is not controlled remains unclear. In addition, the pleiotropic effects of statins on the diabetic heart may differ among statins.

Despite of the determined beneficial effects of statins, when using lipophilic statins (i.e., atorvastatin, simvastatin, or rosuvastatin) in diabetic patients, concerns regarding the progression of glucose intolerance [16] through alteration of insulin sensitivity or glucose uptake by adipocytes remain.[17-21] In contrast to those lipophilic statins, hydrophilic statins such as pravastatin and fluvastatin do not deteriorate glycemic control [12, 16, 19-21] because of the pharmacokinetic differences including hydrophilicity.[11, 22]

Therefore, in the present study, the effect of pravastatin on cardiac function, myocardial fibrosis, oxidative stress, MMP activity and ACE/ACE2 expression was evaluated according to the presence of blood glycemic control in diabetic rat hearts. We hypothesized that early co-treatment of pravastatin and insulin would have additive beneficial effects on cardiac protection than insulin-alone treatment.

## Materials and Methods

This study was reviewed and approved by the Animal Care and Use Committee at Samsung Medical Center (IACUC No. 20140203003), and the animal experiments were conducted in accordance with the Samsung Biomedical Research Institute guidelines for animal experiments.

### Experimental Animal modeling and care

Seven-week-old male Lewis (Inbred Wistar) rats ( $n = 87$ ) were used in this study. All rats were housed at  $22 \pm 3^\circ\text{C}$  with 40-60% humidity in a 12/12-hour light/dark cycle. All animal experiments were performed in a semi-pathogen-free barrier zone at the Samsung Laboratory Animal Research Center. Rats were randomly allocated into one of 5 groups according to the insulin or pravastatin treatment after diabetic modeling: (i) group C (control rats,  $n = 16$ ), (ii) group D (untreated diabetic rats,  $n = 18$ ), (iii) group I (diabetic rats receiving insulin treatment,  $n = 18$ ), (iv) group P (diabetic rats receiving pravastatin treatment,  $n = 17$ ), and (v) group IP (diabetic rats receiving co-treatment of insulin and pravastatin,  $n = 18$ ). Diabetes was induced by an intravenous injection of 65 mg/kg streptozotocin (STZ); in group C, the same volume of citrate buffer (pH 4.5) was administered. Three days after STZ injection, blood glucose levels were measured using a OneTouch Ultra<sup>®</sup> Blood Glucose Meter (LifeScan Inc., Milpitas, CA), and a glucose level higher than 300 mg/dl was considered as a successful diabetic induction. In the groups treated with insulin (group I and group IP), the blood glucose level of each rat was measured twice daily (at 7 a.m. and 7 p.m.) and Lantus<sup>®</sup> (insulin glargine, Sanofi-Aventis,

France) was administered at 2–10 U/kg to achieve a normal blood glucose range for eight weeks from the day of diagnosis. In the statin treatment group (group P and group IP), a calculated dose of pravastatin (20–25 mg/kg/day) was dissolved in water and orally administered once every evening by an oral gavage using a feeding catheter for eight weeks from the day of diagnosis. Standard rat chow and tap water were provided *ad libitum* throughout the study period.

### **Echocardiography**

Eight weeks after treatment, each group of rats was anesthetized with isoflurane/oxygen, and transthoracic echocardiographic images were acquired using a Vevo<sup>®</sup> 2100 high-resolution imaging system (VisualSonics Inc., Toronto, Canada). Two-dimensional parasternal short-axis images were measured at the level of the mid-papillary muscle, and M-mode tracings were recorded. Left ventricular end-diastolic area, left ventricular end-systolic area, left ventricular internal dimension in diastole, and left ventricular internal dimension in systole were measured, and left ventricular fractional area change (LV-FAC) and left ventricular fractional shortening (LV-FS) were calculated as previously described.[8] Mitral peak flow velocities at early diastole and atrial contraction were recorded using a pulsed Doppler technique in parasternal long-axis view, and the ratio of the early (E) to late (A) ventricular filling velocities (E/A ratio) was calculated. All measurements were performed by an experienced technician who was blinded to animal group allocation. Three representative cardiac cycles were analyzed and averaged for each measurement.

## **Biochemical measurements**

After echocardiography, blood glucose levels and body weights were measured. Blood samples were also collected from the abdominal aorta and then immediately centrifuged to measure total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides. Euthanasia was performed by cervical dislocation under deep anesthesia, and the heart was extracted and weighed.

## **Histology and immunohistochemistry**

Hearts extracted from 9-11 rats were formalin fixed, paraffin embedded, and sliced into 4  $\mu\text{m}$  sections. Sections were deparaffinized in xylene, rehydrated in graded alcohol, and transferred to 0.01 M phosphate-buffered saline (PBS, pH 7.4). Myocardial collagen depositions were stained by Masson's trichrome and measured. Conventional immunohistochemistry for collagen I/III, angiotensin converting enzyme (ACE), and ACE2 expressions were performed by the same method as previously described.[8] For analyses, slides were scanned using a ScanScope AT digital slide scanner (Aperio, Vista, CA), and images were analyzed using the Aperio ImageScope Positive Pixel Count algorithm. To quantify immunohistochemical expression, 7 to 10 fields in each slide (at a magnification of 20 times) were randomly chosen and color positivity of pixels within the fields was automatically detected after setting the appropriate input parameters. Color positivity was presented as three different levels, strong positive, moderate positive, and weak positive, according to the strength of the color expression. For further analyses, we defined positivity as follows:

$$\text{Positivity} = \frac{\text{number of (strong positive + moderate positive) pixels}}{\text{total number of pixels in the selected fields}}$$

## **Western blot analysis**

Proteins were extracted from heart tissue obtained from 9-11 rats for each experimental group. Cardiac myocytes were placed on ice for 15 minutes and then sonicated for 30 s; whole-cell protein lysates were recovered by centrifugation. The protein concentration of the supernatant was determined using a Bradford reagent method (Bio-Rad, Hercules, CA, USA). Proteins were resolved by electrophoresis by sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) or native PAGE as appropriate under denaturing conditions. The proteins were transferred to nitrocellulose membranes (BioTrace™ NT, Pall Corp., USA). After blocking in Tris-buffered saline with Tween 20 (TBS-T, 10 mM Tris, 150 mM NaCl, 0.1% Tween 20) containing 5% bovine serum albumin (BSA) for one hour, the membranes were incubated overnight with primary antibody in 3% BSA in TBS-T at 4°C. Membranes were then washed with TBS-T and incubated in 3% BSA in HRP-conjugated IgG secondary antibodies for 1 hour. Membranes were washed again with TBS-T, and the immunocomplexes were detected using a chemiluminescence reagent kit (Amersham Corp., Arlington Heights, IL, USA). The primary antibodies used for immunoblotting studies were collagen I antibody (ab6308, Abcam Inc.), collagen III antibody (ab7778, Abcam Inc.), matrix metalloproteinase (MMP)-2 antibody (ab79271, Abcam Inc.), MMP-9 antibody (ab137867, Abcam Inc.), ACE antibody (ab11734, Abcam Inc.), or ACE2 antibody

(ab87436, Abcam Inc.). Immunoblotting for  $\beta$ -actin was performed to verify equivalent protein loading.

### **Enzyme-linked immunosorbent assay (ELISA)**

The concentration of reactive oxygen species (ROS) in the rat myocardium was measured using a commercial rat ROS ELISA kit (CSB-E15037r, CUSABIO<sup>®</sup>, Wuhan, Hubei, China). In brief, rat heart tissue was mechanically homogenized in PBS and stored overnight at -20 °C. After two freeze-thaw cycles to break the cell membranes, the homogenized samples were centrifuged for 5 min at 5000 rpm and 4 °C. Each supernatant was then transferred into a fresh test-tube and stored at -80 °C, and the level of ROS was determined by ELISA kit following the manufacturer's recommended procedures.

### **Statistical analysis**

All statistical analyses were performed using SPSS for Windows (version 21.0, SPSS Inc., Chicago, IL, USA). Data are presented as median (interquartile range, IQR). Normality of the data distribution was determined with a Shapiro-Wilk test. Differences among groups were tested using a one-way analysis of variance or a Kruskal-Wallis one-way analysis of variance on ranks as appropriate, followed by Tukey's test using ranks for multiple comparisons. In Western blot analysis, the protein expression result in group C was used as a reference (with a reference value of '1'), and a one-sample signed rank test with Bonferroni correction was used when comparing group C with other groups (groups D, I, P and IP). A *P*-value less than 0.05 was considered statistically significant.

# Results

## **Demographic and laboratory characteristics (Lipid profile)**

Diabetes was successfully induced in all rats. Of the 87 rats used in the experiment, 3 rats expired (2 died during diabetic modeling, and 1 from group D died after the echocardiographic exam), and thus 84 rats were included in the final analysis.

Table 1 shows the demographic and laboratory data of the rats after 8 weeks of each treatment. Diabetic rats without glycemic control (group D and group P) showed significantly lower body and heart weights compared with the other groups. For the lipid profile, group D showed the highest blood triglyceride level. However, group P, which was the diabetic group receiving pravastatin single treatment, showed a comparable lipid profile results to groups I and IP. The insulin-treated diabetic group without statin therapy (group I) showed comparable levels of triglycerides and low density lipoproteins with rats on statin therapy (group P and group IP).

## **Echocardiography (cardiac function)**

The echocardiographic data after 8 weeks of treatment are shown in Table 1. The median values of LV-FAC in diabetic rats without glycemic control (group D and group P) were significantly reduced compared with those in the other groups. The values of LV-FS were also lower in group D and group P compared with those in group C and group IP. The E/A ratio, which indicates left ventricular diastolic

function, was significantly lower in group D and group P than in the other groups (Table 1).

### **Histology**

Masson's trichrome was used to stain the cardiac connective tissue blue. There were significant differences in the median cardiac connective tissue fraction among the five groups ( $P < 0.0001$ ). The cardiac connective tissue fraction was significantly higher in the diabetic rats with poor glycemic control (group D and group P) than other groups (Fig. 1). However, there were no significant differences in the cardiac connective tissue fraction among groups C, I and IP (Fig. 1).

### **Collagen and MMP-2, MMP-9 protein cardiac expression**

Immunohistochemistry and Western blot analyses demonstrated that cardiac expression of collagen I and III was significantly increased in group D and group P compared with those in the other groups (Fig. 2 and Fig. 3). Group I showed higher expression of collagen I by immunohistochemistry analysis compared with group C and group IP (Fig. 2A). However, expression of collagen III shown by immunohistochemistry (Fig. 3A) and collagens I and III shown by Western blot analyses results (Fig. 2B and 3B) were comparable among group C, group I, and group IP.

Cardiac expression of MMP-2 and MMP-9 was significantly increased in the high blood glucose groups (group D and group P) as compared with those in other groups as shown by Western blot analyses (Fig. 4). The MMP-2 expression in

group I was higher than group C, which was comparable to the expression level of group IP (Fig. 4A). Group C and group IP showed comparable results in both MMP-2 and MMP-9 expression levels (Fig 4A and 4B).

### **ROS production**

The ELISA demonstrated that the median reactivity of ROS in heart tissue homogenate was significantly increased in group D and group P compared with the other groups (Fig. 5). Group C showed the lowest value of ROS reactivity. No significant differences in ROS reactivity were observed between group I and group IP (Fig. 5).

### **Cardiac ACE and ACE2 protein expression**

In immunohistochemistry analysis, the ACE expression level was significantly lower in group C compared to groups D, I and P, while ACE expression in group IP showed no significant difference from that of the group C (Fig 6A). For ACE2, higher expressions were observed in group C and IP compared to the other groups (Fig 6B). In Western blot analyses, ACE protein expression was significantly lower in groups C and IP than in the other groups (Fig. 6C). In contrast, ACE2 cardiac protein expression was significantly preserved in groups C and IP compared to those in the other groups (Fig 6D).


**Table 1.** Demographic, laboratory and echocardiographic data after eight weeks of treatment

	Group C	Group D	Group I	Group P	Group IP	P value
BWt (g)	387 (375.8-401) <sup>†,‡,§,¶</sup>	226 (215-293)	352 (320-370) <sup>†,§</sup>	246.5 (236-255)	352 (329.5-366) <sup>†,§</sup>	<0.001
HWt (g)	1.18 (1.15-1.27) <sup>†,‡,§</sup>	0.81 (0.77-0.85) <sup>*,‡,¶</sup>	1.07 (0.98-1.11) <sup>*,†,§</sup>	0.87 (0.80-0.92) <sup>*,‡,¶</sup>	1.09 (1.02-1.17) <sup>†,§</sup>	<0.001
HWt/BWt (%)	0.31 (0.3-0.33) <sup>†,§</sup>	0.39 (0.36-0.41) <sup>*,‡,¶</sup>	0.31 (0.3-0.34) <sup>†,§</sup>	0.35 (0.33-0.39) <sup>*,‡</sup>	0.32 (0.31-0.37) <sup>†</sup>	0.002
Blood glucose (mg/dl)	142 (133-153) <sup>†,§</sup>	443 (403-470) <sup>*,‡,¶</sup>	141 (89-149) <sup>†,§</sup>	438 (417-505) <sup>*,‡,¶</sup>	119 (83-151) <sup>†,§</sup>	<0.001
Lipid profile (mg/dl)						
Total cholesterol	82.5 (77-91.5)	93 (85.25-103)	81.5 (72-86)	79.5 (71-81)	88 (84-90)	0.01
Triglyceride	65 (41-77.5) <sup>†</sup>	145 (138-325.5) <sup>*</sup>	124 (86-140) <sup>*†</sup>	92.5 (74-137) <sup>*†</sup>	106 (65-145.5) <sup>*†</sup>	<0.001
HDL	74 (71.5-76.5) <sup>†,‡</sup>	60 (58-74) <sup>*,¶</sup>	68 (60-72) <sup>*,¶</sup>	69 (65-75) <sup>¶</sup>	79 (74-81) <sup>†,‡,¶</sup>	0.004
LDL	11.5 (11-12.5)	15 (10-17.25)	11 (10-13.25)	10 (10-11)	12 (10.25-13)	0.118
Echocardiographic variables						
FAC (%)	61 (58-68) <sup>†,§</sup>	38 (29-43) <sup>*,‡,§,¶</sup>	60 (53-62) <sup>†</sup>	52 (45-56) <sup>*,†,¶</sup>	63 (60-72) <sup>†,§</sup>	<0.001
FS (%)	53 (49-54) <sup>†,‡,§</sup>	39 (37-43) <sup>*,¶</sup>	45 (41-48) <sup>*</sup>	41 (34-45) <sup>*,¶</sup>	53 (41-63) <sup>†,§</sup>	0.0014
E/A ratio	1.8 (1.5-2.5) <sup>†,§</sup>	0.9 (0.8-0.9) <sup>*,‡,¶</sup>	1.8 (1.2-1.9) <sup>†,§</sup>	0.8 (0.7-0.8) <sup>*,‡,¶</sup>	1.7 (1.5-2.3) <sup>†,§</sup>	<0.001

Data are presented as the median (IQR). *P*-values were calculated using a Kruskal-Wallis one-way analysis of variance on ranks. The Tukey test was used for multiple comparisons. BWt = body weight; HWt = heart weight; HDL = high density lipoprotein; LDL = low density lipoprotein; FAC = Fractional area change; FS = Fractional shortening; E/A = the ratio of the early (E) to late (A) ventricular filling velocities.



\**P* < 0.05 vs. group C, †*P* < 0.05 vs. group D, ‡*P* < 0.05 vs. group I, §*P* < 0.05 vs. group P, ¶*P* < 0.05 vs. group IP

**Fig. 1.** Masson's trichrome stain of the myocardium with the connective tissues stained blue. Boxes and lines represent medians and interquartile ranges, respectively. Dots represent the outliers. The upper part represents the images (with 20 times magnification) and the lower part shows the quantitative analysis. \* $P < 0.05$  vs. group D, † $P < 0.05$  vs. group P





**Fig. 2.** Representative micrograph of immunohistochemistry (A) and Western blot photograph for cardiac protein expression (B) of collagen I. Boxes and lines represent medians and interquartile ranges, respectively. Dots represent the outliers. The upper part represents the images (with 20 times magnification in immunohistochemistry) and the lower part shows the quantitative analysis.



\* $P < 0.05$  vs. group D, † $P < 0.05$  vs. group P, ‡ $P < 0.05$  vs. group I




**Fig. 3.** Representative micrograph of immunohistochemistry (A) and Western blot photograph for cardiac protein expression (B) of collagen III. Boxes and lines represent medians and interquartile ranges, respectively. Dots represent the outliers. The upper part represents the images (with 20 times magnification in immunohistochemistry) and the lower part shows the quantitative analysis. \* $P < 0.05$  vs. group D, † $P < 0.05$  vs. group P




**Fig. 4.** Representative Western blot photographs for cardiac protein expression of MMP-2 (A) and MMP-9 (B). Boxes and lines represent medians and interquartile ranges, respectively. Dots represent the outliers. \* $P < 0.05$  vs. group D, † $P < 0.05$  vs. group P, ‡ $P < 0.05$  vs. group I. MMP, matrix metalloproteinase





**Fig. 5.** Cardiac expressions of reactive oxygen species measured by enzyme-linked immunosorbent assay. Boxes and lines represent medians and interquartile ranges, respectively. Dots represent the outliers. \* $P < 0.05$  vs. group D, † $P < 0.05$  vs. group P, ‡ $P < 0.05$  vs. group I, § $P < 0.05$  vs. group IP



**Fig. 6.** Representative micrographs of immunohistochemistry for ACE (A) and ACE2 (B), and Western blot photographs for cardiac protein expression for ACE (C) and ACE2 (D). Boxes and lines represent medians and interquartile ranges, respectively. Dots represent the outliers. The upper part represents the images (with 20 times magnification in immunohistochemistry) and the lower part shows the quantitative analysis. \* $P < 0.05$  vs. group D, † $P < 0.05$  vs. group P, ‡ $P < 0.05$  vs. group I. ACE, angiotensin converting enzyme





# Discussion

## Major findings

In this experimental study, we observed the cardiac effects of pravastatin under two different conditions of blood glucose control in the STZ-induced diabetic rat model. Under poor glycaemic control, diabetic rats showed significantly impaired cardiac function and increased levels of cardiac fibrosis and ROS production regardless of pravastatin treatment. When blood glucose levels were well controlled from the early stage of diabetes with insulin, diabetic rats showed comparable results with non-diabetic rats in cardiac function, fibrosis, MMP expression and ROS production, regardless of additional treatment with oral pravastatin. Although cardiac ACE2 expression seemed to be more preserved in the combination treatment group receiving pravastatin and insulin than in the insulin-alone group, this did not lead to meaningful differences in other outcomes in our study.

## Pathophysiology of diabetic cardiomyopathy and Statin

Diabetic cardiomyopathy is defined as left ventricular dysfunction in diabetic patients without coronary artery disease or other potential etiological conditions[18] and, morphologically, is mainly characterized by cardiac hypertrophy and adverse remodeling associated with myocardial fibrosis. The pathogenesis of diabetic cardiomyopathy has a multifactorial basis. Several suggested mechanisms include metabolic disturbances, insulin resistance, microvascular disease, renin-angiotensin system activation, and excessive oxidative stress.[5] Among the various

mechanisms, the role of oxidative stress has been strongly suggested in many studies, [19-22] and therefore beneficial effects of statins and antioxidant treatments on the management of diabetic complications have been extensively investigated and reported.

### **Results of our study**

Previously, we suggested that a combination of fluvastatin and insulin may be more effective than insulin-alone treatment in diabetic hearts with regard to reducing myocardial fibrosis and preserving cardiac function and ACE2 expression.[8] However, in that study, the sole effect of fluvastatin on diabetic cardiomyopathy could not be explained because of the absence of an experimental group receiving a single fluvastatin treatment. In the present study, we included experimental groups observing both the sole effect of each treatment (group I or group P) and the effect in combination (group IP) on diabetic rat hearts. Our results suggest that glycemic control is the primary factor involved in reducing the progression of diabetic cardiomyopathy. Contrary to our expectations, once blood glucose was well controlled with insulin, the addition of pravastatin treatment did not make a significant difference in most of the study outcomes. Two insulin-treated groups with good glycemic control (group I vs. group IP) showed comparable results regardless of the use of pravastatin in cardiac function, fibrosis, collagen expression, MMP activation, or ROS production.

Moreover, between the two diabetic groups without glycemic control (group D vs. group P), pravastatin treatment did not bring any beneficial effects compared to the un-treated group showing comparable progression of diabetic cardiomyopathy.

These results are inconsistent with previous findings that statin treatment itself was effective in reducing myocardial fibrosis and cardiac dysfunction in the diabetic condition without specific comments for glycemic control.[7]

There are several explanations for the results of our study. First, because we started and maintained good glycemic control from a very early stage of diabetes, diabetic complications may have been prevented or delayed in the insulin-treated rats during our study period. In clinical practice, a chronic hyperglycemic period generally exists until the initial diagnosis of diabetes, and in this situation, increased levels of inflammatory proteins and oxidative stress are not completely restored even with the later normalization of blood glucose.[23] This phenomenon results from “glycemic memory,” in that once ROS production is increased in the early hyperglycemic environment, ROS-induced cellular dysfunction and mitochondrial DNA damage may occur and persist independently with later glycemic control. Secondly, the different dosage of pravastatin used for treatment in our study (20 - 25 mg/kg/day) may have affected our results. In previous experimental studies, much higher doses of pravastatin (100 mg/kg/day) effectively reduced cardiac fibrosis and MMP activity. [24] Another pravastatin study, which showed the preventive effect of cardiovascular remodeling in a type II diabetic model, also used higher dose of pravastatin (100 mg/kg/day).[7] However, considering that the recommended dosage of pravastatin is 40 mg/day in human clinical practice, the pravastatin dosage we used was not an underdose for rats of much smaller size than human. Third, the results may be due to the unique pharmacokinetic characteristics of pravastatin such as lower plasma protein binding, hydrophilic nature, different primary metabolic pathways, and dual routes

of elimination.[17, 25, 26] Pravastatin has shown different effects on the progression of glucose intolerance[11, 12] and side effects compared with other statins.[27] Moreover, in a previous study, which observed the effects of various statins for MMP activity and vascular smooth muscle proliferation, only pravastatin showed different results from other statins (fluvastatin, simvastatin, lovastatin, and atorvastatin). [28]

### **Statin and ACE2**

Interestingly, cardiac ACE2 expression was more preserved in the pravastatin-treated group among glucose-controlled rats in our study. However, this did not lead to a meaningful difference in the levels of cardiac fibrosis or ROS production. The effects of pravastatin might not have been high enough to sufficiently reduce the MMP upregulation or cardiac collagen deposition. In our previous study, additive treatment with fluvastatin in glucose-controlled diabetic rats led to more preserved cardiac ACE2 expression as well as in the cardiac fibrosis and diastolic cardiac function than did the insulin-only treated group. Although fluvastatin is less potent than pravastatin with regard to lipid lowering effects, the differences in pleiotropic effects among statins remain unclear because there are insufficient data.

### **Potential benefits of hydrophilic statins in diabetic patients**

When making a therapeutic selection between statin agents in diabetic patients for primary prevention purpose, there are some factors that must be considered. Although all statins are generally well tolerated, some side effects such as drug interactions, muscle toxicity, insomnia, and cognitive dysfunction have been

related to statin use. These side effects are more likely to occur with the use of lipophilic statins. In this regard, hydrophilic statins have some advantages compared to lipophilic statins especially in diabetic or elderly patients taking multiple medications. Among hydrophilic statins, pravastatin has not deteriorated glycemic control and is less likely to displace albumin-bound drugs such as warfarin because of its lower plasma protein binding.[26] Moreover, in clinical situations where patients must receive multiple medications, pravastatin may have the fewest drug interactions because it is not metabolized by CYP450.[17] In patients with impaired renal function, fluvastatin is preferred because fluvastatin is the drug that is least affected by renal elimination.[17] However, further evaluation is needed to identify appropriate agents and adequate doses to provide optimal therapeutic efficacy including the pleiotropic effect of statins for each individual patient's condition.

### **Study limitations**

There were several limitations in our study. First, since we started glycemic control immediately after the confirmation of diabetic induction, there was no experimental group with a chronic hyperglycemic period before starting insulin treatment, and we did not observe the effect of statin under such condition with glycemic memory, which is common in the real life clinical situation. Second, we did not observe the long-term effects of pravastatin after 8 weeks. Although 8 weeks is sufficient to develop diabetic cardiomyopathy in the groups without glycemic control, a longer follow-up might be needed in groups with controlled-blood glucose because the onset and progression of diabetic cardiomyopathy may

be delayed under good glycemic control. Moreover, lipid profiles were normalized in the pravastatin-treated groups, and therefore long-standing use of statins may make a difference even between the groups with poor glucose control because dyslipidemia may also play a role in the development of microvascular complications.[5, 29, 30] Third, we used semi-quantitative methods to analyze the study outcomes (immunostaining, Western blotting, and ELISA), although they are popular techniques used in biomedical research. Fourth, our experimental model was type I diabetes induced by STZ injection. Although the STZ-induced diabetic rat model is an established experimental model for research of diabetic cardiomyopathy [8, 9, 31, 32] and models of type 1 and type 2 diabetes have been used interchangeably to understand pathophysiological mechanisms of diabetic cardiomyopathy,[32] it is difficult to extend our study results to all diabetic conditions. Finally, the lipid-lowering effect of statin would be different in rodents; therefore, rat models might not be perfect to evaluate the effects of statin. However, in this experimental study, we aimed to evaluate the pleiotropic effects of statin independent from its lipid-lowering effects. Moreover, many previous studies have used rats or mice to evaluate the protective effects of statin on the cardiovascular system.

## **Conclusions**

In conclusion, this experimental study with type 1 diabetic rat models revealed that glycemic control is the primary condition attenuating the progression of diabetic cardiomyopathy even with pravastatin treatment. Further studies may be

needed to identify a regimen for optimal pleiotropic effects of pravastatin on the heart in different types of diabetes.

## References

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr., Sowers JR (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* 100:1134-1146
2. Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G (2013) Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. *World J Diabetes* 4:177-189
3. Falcao-Pires I, Leite-Moreira AF (2012) Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. *Heart Fail Rev* 17:325-344
4. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am J Cardiol* 30:595-602
5. Singh VP, Baker KM, Kumar R (2008) Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. *Am J Physiol Heart Circ Physiol* 294:H1675-1684
6. (2015) (8) Cardiovascular disease and risk management. *Diabetes Care* 38 Suppl:S49-57
7. Chen YH, Feng B, Chen ZW (2012) Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without

- established cardiovascular diseases: a meta-analysis. *Exp Clin Endocrinol Diabetes* 120:116-120
8. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 371:117-125
  9. Shida T, Nozawa T, Sobajima M, Ihori H, Matsuki A, Inoue H (2014) Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature. *Heart Vessels* 29:532-541
  10. Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. *Am J Cardiol* 96:24F-33F
  11. Gazzo P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M (2012) Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev* 64:102-146
  12. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, Takeuchi H, Mizushige K, Kohno M (2004) Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. *J Am Coll Cardiol* 44:904-913
  13. Shin YH, Min JJ, Lee JH, Kim EH, Kim GE, Kim MH, Lee JJ, Ahn HJ (2016) The effect of fluvastatin on cardiac fibrosis and angiotensin-

converting enzyme-2 expression in glucose-controlled diabetic rat hearts.

Heart Vessels

14. Dai QM, Lu J, Liu NF (2011) Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. *Chin Med J (Engl)* 124:89-94
15. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A (2000) Pleiotropic effects of statins in atherosclerosis and diabetes. *Diabetes Care* 23 Suppl 2:B72-78
16. Kanda M, Satoh K, Ichihara K (2003) Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. *Biol Pharm Bull* 26:1681-1684
17. Muscogiuri G, Sarno G, Gastaldelli A, Savastano S, Ascione A, Colao A, Orio F (2014) The good and bad effects of statins on insulin sensitivity and secretion. *Endocr Res* 39:137-143
18. Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M, Sugi K (2006) Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. *Intern Med* 45:51-55
19. Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, Oikawa S, Yamada N, Shimano H (2006) Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. *J Atheroscler Thromb* 13:329-335

20. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K (2008) Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. *J Pharmacol Sci* 107:80-89
21. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EK (2009) Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. *Atherosclerosis* 204:483-490
22. Chong PH, Seeger JD, Franklin C (2001) Clinically relevant differences between the statins: implications for therapeutic selection. *Am J Med* 111:390-400
23. Ernande L, Derumeaux G (2012) Diabetic cardiomyopathy: myth or reality? *Arch Cardiovasc Dis* 105:218-225
24. Seddon M, Looi YH, Shah AM (2007) Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. *Heart* 93:903-907
25. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. *Circ Res* 107:1058-1070
26. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS (2001) Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. *Circ Res* 88:1291-1298
27. Huynh K, Bernardo BC, McMullen JR, Ritchie RH (2014) Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol Ther* 142:375-415
28. Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. *Kidney Int Suppl* 77:S26-30

29. Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, Yokota M (2006) Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. *Cardiovasc Res* 69:726-735
30. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. *Clin Pharmacokinet* 39:397-412
31. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fundam Clin Pharmacol* 19:117-125
32. Bitzur R, Cohen H, Kamari Y, Harats D (2013) Intolerance to statins: mechanisms and management. *Diabetes Care* 36 Suppl 2:S325-330
33. Leiter LA (2005) The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? *Diabetes Res Clin Pract* 68 Suppl 2:S3-14
34. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 16:434-444
35. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ (2007) Recipes for creating animal models of diabetic cardiovascular disease. *Circ Res* 100:1415-1427
36. Bugger H, Abel ED (2009) Rodent models of diabetic cardiomyopathy. *Dis Model Mech* 2:454-466

## 요약 (국문 초록)

**배경 및 목적** : 스타틴 치료가 당뇨 환자에서 당뇨병성 심근병증의 진행을 지연시키는 보호효과가 있다고 알려졌지만, 동반된 혈당 조절 여부가 스타틴의 보호효과에 어떤 영향을 주는지에 대하여는 명확히 알려져 있지 않다. 본 연구에서는 스타틴의 당뇨병성 심장에 대한 보호 효과를 동반된 혈당조절 유무에 따라 관찰하였다.

**방법** : 7 주령 male Lewis rat 87 마리를 무작위로 배정하여 다음의 5 군으로 분류하였다: 대조군 (C 군), 치료하지 않은 당뇨쥐 (D 군), 경피 인슐린으로 혈당조절한 당뇨쥐 (I 군), 혈당조절 없이 프라바스타틴 복용만 한 당뇨쥐 (P 군), 그리고 혈당조절과 함께 프라바스타틴을 복용한 당뇨쥐 (IP 군). 꼬리정맥에 streptozotocin (65 mg/kg)을 주사하여 type I 당뇨병을 유발한 뒤, 각 군 배정에 따라 인슐린(2-10 U/kg, twice a day)과 프라바스타틴 (20-25 mg/kg/day) 치료를 시행한다. 8 주 뒤 심초음파와 혈액 검사 시행 후 심장을 적출하여 심근섬유화 정도 (Masson' s trichrome stain ), collagen I/III, matrix metalloproteinase (MMP)-2, MMP-9, 그리고 angiotensin converting enzyme (ACE)/ACE2 의 심장 발현 정도를 조직학적 검사와 웨스턴 블롯 분석을 이용하여 비교 관찰한다. 또한 각 군별 심근 내 유해활성산소 발현을 Enzyme-linked immunosorbent assay 방법으로 비교한다.

**결과 :** 혈당조절을 하지 않았던 당뇨쥐 군 (D 군과 P 군)에서 유의한 심근이완기능의 저하 및 심근섬유화 증가, collagen I/III, MMP-2, 그리고 MMP-9 의 심근 발현의 증가가 관찰되었다. 활성산소기의 발생 또한 D 군과 P 군에서 다른 그룹에 비해 유의하게 증가하였다. 그러나, 인슐린을 이용하여 혈당 조절을 시행하 그룹에서는 (I 군과 IP 군) 프라바스타틴의 추가 복용 여부와는 관계없이 대부분의 지표에서 대조군과 유사한 결과를 보였다. 다만, 안지오텐신 전환효소 2 의 심장 발현은 타 군에 비해 IP 군에서 대조군과 유사하게 보존되었다.

**결론 :** 본 연구 결과 스타틴의 복용보다는 인슐린을 이용한 혈당조절이 제 1 형 당뇨병성 심근병증의 진행을 지연시키는 주된 보호 기전으로 생각된다. 당뇨병성 심근병증에서 스타틴의 보호효과를 위한 이상적인 조건에 대하여는 추가적인 연구가 필요할 것이다.

**주요어:** 프라바스타틴, 인슐린, 당뇨병성 심근병증, 심근 섬유화, 안지오텐신 전환효소 2, 산화 스트레스

**학번:** 2013-30541